Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Pasithea Therapeutics Corp ( (KTTA) ) is now available.
On September 3, 2025, Pasithea Therapeutics Corp. held its Annual Meeting of Stockholders, where several key proposals were approved. These included an amendment to the 2023 Stock Incentive Plan, increasing authorized shares by 1,750,000 to a total of 2,014,221, and the election of two Class II directors. Additionally, stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. A significant decision was also made to adopt an amendment allowing a reverse stock split of the company’s shares, with the ratio to be determined by the Board of Directors. These decisions reflect strategic moves to enhance the company’s financial structure and governance.
More about Pasithea Therapeutics Corp
Average Trading Volume: 148,867
Technical Sentiment Signal: Sell
Current Market Cap: $6.02M
For a thorough assessment of KTTA stock, go to TipRanks’ Stock Analysis page.